Practice
Featured experience
Emerson $7.2 billion acquisition of remaining outstanding shares of AspenTech
We are advising Emerson on its acquisition
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction
Emerson proposal to acquire AspenTech at $15.3 billion enterprise valuation
We are advising Emerson on its proposal to acquire the remaining outstanding shares of AspenTech
ATSG $3.1 billion acquisition by Stonepeak
We are advising Air Transport Services Group on its going-private transaction
Altair Engineering $10.6 billion acquisition by Siemens
We are advising Altair on the transaction
Nippon Paint Holdings $2.3 billion AOC acquisition
We are advising Nippon Paint on the acquisition
Atlantic Union Bankshares $1.6 billion acquisition of Sandy Spring Bancorp
We are advising Atlantic Union Bankshares on the acquisition
Crane NXT £300 million acquisition of De La Rue’s authentication division
We are advising Crane NXT on the acquisition
Arcadium Lithium $6.7 billion acquisition by Rio Tinto
We are advising Arcadium Lithium on the transaction
Telemos Capital investment partnership with Helios Global Group
We are advising Telemos Capital on the transaction
TPG Capital strategic investment in Creative Planning
We advised TPG on the transaction